Pegdinetanib (BMS-844203), an anti-angiogenic therapeutic agent, exemplifies a new class of targeted biologics called Adnectins. Adnectins are genetically engineered variants of the tenth type III domain of human fibronectin. Firstly, Adnectins are small proteins and have a high affinity to antibodies. Secondly, they are not glycosylated and have no...